Oscar Health (NYSE: OSCR) has quietly become one of the most compelling digital health turnaround stories in the market today. While recent price action shows the stock pulling back from its 2024 highs, I see this as a rare second-chance opportunity—not a red flag. My conviction in Oscar remains strong, and I'm taking this correction as a chance to accumulate shares before the market fully prices in its transformation.

At its core, Oscar is a tech-driven health insurer that's disrupting a bloated and outdated system. What sets Oscar apart is its focus on member experience, data-driven underwriting, and scalable infrastructure. The company is finally reaching an inflection point: after years of heavy investment, Oscar turned adjusted EBITDA positive in 2024 and is projecting breakeven or better on a GAAP basis in 2025. Their insurance margin has also improved significantly, suggesting underwriting discipline is kicking in. These are not promises—they're actual financial improvements.

Yes, the stock has pulled back—but so has sentiment across the entire health insurance sector due to noise around regulatory risks and medical cost trends. For me, that's just market overreaction. Oscar's disciplined focus on efficiency, narrow networks, and direct-to-consumer enrollment give it structural advantages over legacy players. The long-term story remains intact, and I'm using this dip to accumulate with a multiyear view in mind. In a few quarters, I believe the market will revisit Oscar's narrative—not as a speculative bet, but as a proven, profitable disruptor in managed care.

What gives me added confidence is Oscar's continued ability to grow its member base in a competitive landscape without sacrificing margin. While large incumbents struggle with bloated cost structures and slow innovation, Oscar has leaned into automation and digital onboarding, allowing it to scale efficiently. Their proprietary tech stack gives them real-time insights into claims data and patient behavior—something traditional insurers are still scrambling to figure out. That kind of agility matters in a margin-sensitive, policy-driven industry.

From a valuation perspective, OSCR still trades at a steep discount to its future potential. Most investors are still pricing it as a high-risk growth name, not recognizing the shift toward financial stability that's already underway. Once Oscar delivers consistent profitability and expands into adjacent verticals like value-based care or Medicaid, I believe institutional capital will flood back in. Until then, I'm happy to build my position quietly during this pullback—before the market catches on.

@TigerStars  @Tiger_comments  @CaptainTiger